Description: VolitionRX Limited, a development stage life sciences company, focuses on developing cancer detection blood tests for detecting and diagnosing cancer and other diseases. It develops two blood tests in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides; and three blood tests in the NuQ-V family to detect cancer and nucleosomes containing specific histone variants. The company also develops nine blood tests in the NuQ-M family to detect cancer by detecting nucleosomes containing modified histones, the proteins that package, and order DNA into nucleosomes; and five blood tests in the NuQ-A family to detect cancer by detecting nucleosome-protein adducts, as well as offers research kits. It develops HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help appropriate therapy; NuQ Endo endometriosis test; and NuQ clinical diagnostic products. VolitionRX Limited is based in Singapore.
Home Page: www.volition.com
VNRX Technical Analysis
13215 Bee Cave Parkway
Austin,
TX
78738
United States
Phone:
646 650 1351
Officers
Name | Title |
---|---|
Dr. Martin Charles Faulkes Ph.D. | Exec. Chairman |
Mr. Cameron Reynolds MBA | Founder, Group CEO, Pres & Director |
Mr. Terig Hughes | Group CFO & Treasurer |
Dr. Jacob Vincent Micallef | Chief Scientific Officer |
Dr. Salvatore Thomas Butera | Chief Exec. Officer of Volition Veterinary Diagnostics Devel. LLC |
Dr. Gaetan Michel Ph.D. | Chief Operating Officer |
Dr. Mark Eccleston M.B.A., Ph.D. | Chief Technology Officer |
Mr. Scott Powell Ph.D. | Exec. VP of Investor Relations & CFO of Volition America Inc |
Mr. Nicholas Plummer | Group Gen. Counsel |
Ms. Louise Batchelor Day | Chief Marketing & Communications Officer |
Exchange: NYSE MKT
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Health Care Equipment & Services |
GIC Industry: | Health Care Equipment & Supplies |
GIC Sub-Industry: | Health Care Supplies |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 35.2345 |
Price-to-Sales TTM: | 563.9999 |
IPO Date: | 2007-04-25 |
Fiscal Year End: | December |
Full Time Employees: | 83 |